Veliparib

Biotechs Working on Potential Preventive Measures and Cancer Treatments

Retrieved on: 
Tuesday, March 30, 2021
Clinical medicine, Medicine, Cancer, Oncology, Breast cancer, Treatment of cancer, Ovarian cancer, Melanoma, Metástasis, Veliparib, Adjuvant therapy

Jeremy Sobotta, CEO at Perimeter Medical, stated , "our novel technology is addressing an unmet need in breast cancer surgery.

Key Points: 
  • Jeremy Sobotta, CEO at Perimeter Medical, stated , "our novel technology is addressing an unmet need in breast cancer surgery.
  • This tool has the potential to change the future of cancer treatments and reduce the likelihood of a second operation.
  • Syndax Pharmaceuticals (NASDAQ:SNDX) announced last April that the biotech company was in the early stages of a potential blood cancer treatment .
  • The company has been involved in several clinical trials for products that target breast cancer, metastatic melanoma, lung cancer, solid tumors, ovarian cancer, and beyond.

Biotechs Working on Potential Preventive Measures and Cancer Treatments

Retrieved on: 
Tuesday, March 30, 2021
Clinical medicine, Medicine, Cancer, Oncology, Breast cancer, Treatment of cancer, Ovarian cancer, Melanoma, Metástasis, Veliparib, Adjuvant therapy

Jeremy Sobotta, CEO at Perimeter Medical, stated , "our novel technology is addressing an unmet need in breast cancer surgery.

Key Points: 
  • Jeremy Sobotta, CEO at Perimeter Medical, stated , "our novel technology is addressing an unmet need in breast cancer surgery.
  • This tool has the potential to change the future of cancer treatments and reduce the likelihood of a second operation.
  • Syndax Pharmaceuticals (NASDAQ:SNDX) announced last April that the biotech company was in the early stages of a potential blood cancer treatment .
  • The company has been involved in several clinical trials for products that target breast cancer, metastatic melanoma, lung cancer, solid tumors, ovarian cancer, and beyond.

Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, January 13, 2021
Biotechnology, FDA, Diabetes, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical trials, Health sciences, Clinical medicine, Lung cancer, Health, Non-small-cell lung carcinoma, Clinical trial, Treatment of lung cancer, Veliparib

This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.

Key Points: 
  • This production provides supply of REQORSA for our two upcoming Acclaim clinical trials and advances our mission to develop innovative new treatments for non-small cell lung cancer patients greatly in need of effective therapy options.
  • The Company also reported the completion of the manufacturing scale-up for the clinical-grade production of REQORSA , subject to final testing that was underway.
  • From there, REQORSA supply will be delivered to the clinical trial sites pending FDA clearance to commence the clinical trials.
  • The Companys lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

Global Brain Cancer Clinical Trials Review: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
Monday, May 11, 2020
Health, Oncology, Clinical trials, Health, Clinical research, Medical research, Pharmaceutical industry, Clinical pharmacology, Design of experiments, Clinical trial, Patient recruitment, Veliparib

The "Brain Cancer Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brain Cancer Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The "Brain Cancer Global Clinical Trials Review, H1, 2020" report provides top line data relating to the clinical trials on Brain Cancer.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

2019 Post European Society for Medical Oncology (ESMO) Report: Highlights from ESMO 2019 Congress - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019
Health, Oncology, Cancer, Clinical medicine, Infectious causes of cancer, Antineoplastic drugs, Breakthrough therapy, Merck, Atezolizumab, Genentech, Pembrolizumab, Veliparib, Small-cell carcinoma, Oncology

Pemigatinib for Biliary Tract Cancer (INCY, Phase III)

Key Points: 
  • Pemigatinib for Biliary Tract Cancer (INCY, Phase III)
    Tibsovo for Biliary Tract Cancer (AGIO, Phase III)
    Enfortumab Vedotin for Bladder Cancer (Astellas, BLA)
    Sacituzumab Govitecan for Bladder Cancer (IMMU, Phase II)
    Tecentriq for Bladder Cancer (RHHBY, Approved)
    G1T48 for Breast Cancer (G1 Therapeutics, Phase I)
    Keytruda for Breast Cancer (MRK, Phase III)
    Keytruda for Breast Cancer (MRK, Phase III)
    Kisquali for Breast Cancer (NVS, Approved)
    Trilaciclib for Breast Cancer (G1 Therapeutics, Phase II)
    Verzenio for Breast Cancer (LLY, Approved)
    AMG 510 for Colorectal Cancer (CRC) (AMGN, Phase I)
    Braftovi for Colorectal Cancer (CRC) (PFE, Phase III)
    Tucatinib for Colorectal Cancer (CRC) (PFE, Phase III)
    Opdivo for Esophageal Cancer (BMY, Phase III)
    Margetuximab for Gastric Cancer (MGNX, Phase II)
    Debio 1143 for Head and Neck Cancer (Debiopharm, Phase II)
    Monalizumab for Head and Neck Cancer (AZN, Phase II)
    Opdivo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (BMY, Approved)
    Tecentriq for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (RHHBY, Phase III)
    AMG 510 for Non-Small Cell Lung Cancer (NSCLC) (AMGN, Phase I)
    Opdivo for Non-Small Cell Lung Cancer (NSCLC) (BMY, Approved)
    Tagrisso for Non-Small Cell Lung Cancer (NSCLC) (AZN, Approved)
    Tecentriq for Non-Small Cell Lung Cancer (NSCLC) (RHHBY, Approved)
    AVB-500 for Ovarian Cancer (ARAV, Phase II)
    Lynparza for Ovarian Cancer (AZN, Approved)
    M6620 for Ovarian Cancer (MKGAY, Phase II)
    Mirvetuximab Soravtansine for Ovarian Cancer (IMGN, Phase III)
    Veliparib for Ovarian Cancer (ABBV, Phase III)
    Zejula for Ovarian Cancer (GSK, Approved)
    Erleada for Prostate Cancer (JNJ, Approved)
    Lynparza for Prostate Cancer (AZN, Phase III)
    Rubraca for Prostate Cancer (CLVS, Phase III)
    SM-88 for Prostate Cancer (TYME, Phase II)
    Zejula for Prostate Cancer (GSK, Phase III)
    Mavorixafor for Renal Cell Cancer (RCC) (XFOR, Phase II)
    MK-6482 for Renal Cell Cancer (RCC) (MRK, Phase II)
    Tivopath (Oncology) for Renal Cell Cancer (RCC) (AVEO, Phase III)
    ALRN-6924 for Solid Tumors (ALRN, Phase II)
    Selpercatinib for Thyroid Cancer (LLY, Phase II)
    View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005353/en/